Checkpoint Capital
Latest statistics and disclosures from Checkpoint Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are RYTM, ARGX, AXSM, AVDL, PTGX, and represent 75.29% of Checkpoint Capital's stock portfolio.
- Added to shares of these 10 stocks: AVDL (+$16M), AXSM (+$13M), PHAT, RYTM, PTGX, PLRX, KYMR, CDTX, SLNO, ATYR.
- Started 5 new stock positions in AVDL, KYMR, PLRX, SLNO, CDTX.
- Reduced shares in these 9 stocks: Flamel Technologies Sa (-$12M), MIRM (-$9.1M), , VSTM, GHRS, CORT, Atara Biotherapeutics, ALLK, TRVI.
- Sold out of its positions in Atara Biotherapeutics, Flamel Technologies Sa, IRWD, MIRM, VSTM, GHRS.
- Checkpoint Capital was a net buyer of stock by $16M.
- Checkpoint Capital has $166M in assets under management (AUM), dropping by 10.86%.
- Central Index Key (CIK): 0001977548
Tip: Access up to 7 years of quarterly data
Positions held by Checkpoint Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Checkpoint Capital
Checkpoint Capital holds 16 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Rhythm Pharmaceuticals (RYTM) | 22.8 | $38M | +11% | 922k | 41.06 |
|
| Argenx Se Sponsored Adr (ARGX) | 21.3 | $35M | 82k | 430.04 |
|
|
| Axsome Therapeutics (AXSM) | 14.1 | $23M | +119% | 291k | 80.50 |
|
| Avadel Pharmaceuticals Com Shs (AVDL) | 9.6 | $16M | NEW | 1.1M | 14.06 |
|
| Protagonist Therapeutics (PTGX) | 7.4 | $12M | +26% | 355k | 34.65 |
|
| Cytokinetics Com New (CYTK) | 6.2 | $10M | 190k | 54.18 |
|
|
| Phathom Pharmaceuticals (PHAT) | 5.4 | $9.0M | +96% | 875k | 10.30 |
|
| Corcept Therapeutics Incorporated (CORT) | 4.8 | $8.0M | -10% | 245k | 32.49 |
|
| Atyr Pharma Com New (ATYR) | 1.8 | $3.0M | +34% | 1.9M | 1.56 |
|
| Pliant Therapeutics (PLRX) | 1.5 | $2.5M | NEW | 232k | 10.75 |
|
| Kymera Therapeutics (KYMR) | 1.5 | $2.4M | NEW | 82k | 29.85 |
|
| Cidara Therapeutics Com New (CDTX) | 1.0 | $1.7M | NEW | 145k | 11.94 |
|
| Trevi Therapeutics (TRVI) | 0.9 | $1.5M | 500k | 2.98 |
|
|
| Applied Therapeutics (APLT) | 0.6 | $1.1M | +3% | 228k | 4.67 |
|
| Soleno Therapeutics (SLNO) | 0.5 | $804k | NEW | 20k | 40.80 |
|
| Allakos (ALLK) | 0.4 | $650k | -15% | 650k | 1.00 |
|
Past Filings by Checkpoint Capital
SEC 13F filings are viewable for Checkpoint Capital going back to 2023
- Checkpoint Capital 2024 Q2 filed Aug. 14, 2024
- Checkpoint Capital 2024 Q1 filed May 15, 2024
- Checkpoint Capital 2023 Q4 filed Feb. 14, 2024